Zimbabwe

The Medicines Control Authority of Zimbabwe (MCAZ) is the primary national health regulatory authority responsible for the regulation of medicines, medical devices, diagnostics, and related health products in Zimbabwe. It operates under the Medicines and Allied Substances Control Act (Chapter 15:03), which governs the registration, importation, distribution, and post-market surveillance of health products. All health products must be registered with the MCAZ before they can be legally marketed or distributed in Zimbabwe. The registration process involves a formal application review that assesses safety, quality, and efficacy data, and the MCAZ may conduct facility inspections and request additional information during the evaluation period.

Applications to the MCAZ are generally required to be submitted in Common Technical Document (CTD) format, and the authority also accepts submissions aligned with the African Union's African Common Technical Document (ACTD) standard, reflecting its participation in regional harmonization initiatives under the African Medicines Regulatory Harmonization (AMRH) program. Applicants must appoint a local authorized representative or registered importer based in Zimbabwe to facilitate regulatory correspondence and post-market obligations. The MCAZ has undertaken reforms in recent years to streamline its processes, including reliance pathways that allow expedited review for products already approved by stringent regulatory authorities such as the US FDA, EMA, or WHO-prequalified bodies. Fee structures, dossier completeness requirements, and labeling compliance with local standards are all critical considerations for a successful submission.

Public procurement of health products in Zimbabwe is primarily coordinated through the Ministry of Health and Child Care (MoHCC), which sets national health priorities and oversees the allocation of health commodities across public facilities. The National Pharmaceutical Company of Zimbabwe (NatPharm) serves as the central procurement and distribution agency for essential medicines and health supplies destined for the public sector, operating as the main warehousing and logistics body for the government. Procurement decisions are subject to the Public Procurement and Disposal of Public Assets Act (Chapter 22:23), administered by the Procurement Regulatory Authority of Zimbabwe (PRAZ), which mandates competitive tendering processes for government purchases above prescribed thresholds. The Zimbabwe Essential Medicines List (ZEML) guides formulary decisions and influences which products are prioritized for public procurement.

Zimbabwe's public health system is heavily supported by international donor and multilateral channels, which represent a significant portion of total health commodity financing. Key partners include the Global Fund to Fight AIDS, Tuberculosis and Malaria, PEPFAR (administered through USAID), UNICEF, and the World Health Organization (WHO), all of which procure and supply health products through their own international tendering mechanisms, often requiring WHO prequalification or stringent regulatory authority approval as a prerequisite. Gavi, the Vaccine Alliance, also plays an important role in financing immunization commodities. The private sector, comprising private pharmacies, clinics, and hospitals, procures health products through registered local importers and distributors operating under MCAZ authorization. While Zimbabwe does not currently enforce strong formal local manufacturing preference policies, the government has expressed strategic intent to strengthen domestic pharmaceutical manufacturing capacity in alignment with the Africa Medicines Manufacturing Plan and continental self-reliance goals.